Roche, VTT to Collaborate on Cancer Drug, Biomarker Studies | GenomeWeb
NEW YORK (GenomeWeb News) – Turku, Finland-based VTT today said that it is collaborating with Roche on research studies for an unnamed Roche cancer drug and potential predictive biomarkers.
 
VTT said the studies will use its high-throughput screening, RNA interference, cell biology, and bioinformatics capabilities. The firm said it would conduct the research at its facilities in Finland.
 
Terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.